Status:
COMPLETED
Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotec...
Eligibility Criteria
Inclusion
- locally advanced pancreatic cancer
- performance status 0-2
- normal blood count and chemistry
- no previous chemotherapy or radiotherapy
Exclusion
- serious concurrent systemic disease
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
September 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00192712
Start Date
November 1 2002
End Date
September 1 2010
Last Update
November 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Rambam Medical Center
Haifa, Israel, 31096